SLS International (SLS) Receives New Coverage from Analysts at Oppenheimer

Oppenheimer assumed coverage on shares of SLS International (AMEX:SLS) in a report released on Thursday, MarketBeat reports. The brokerage issued an outperform rating and a $13.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on the company. Maxim Group reaffirmed a buy rating and issued a $5.00 price target on shares of SLS International in a research note on Monday, October 22nd. Zacks Investment Research raised SLS International from a hold rating to a buy rating and set a $1.25 price target on the stock in a research note on Friday, August 3rd. Finally, HC Wainwright set a $4.00 price target on SLS International and gave the stock a buy rating in a research note on Tuesday, July 31st. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. SLS International has a consensus rating of Buy and an average target price of $5.81.

Shares of AMEX SLS opened at $0.00 on Thursday.

SLS International (AMEX:SLS) last announced its quarterly earnings results on Wednesday, August 15th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($0.23).

SLS International Company Profile

SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards.

Further Reading: Short Selling – Explanation For Shorting Stocks

Analyst Recommendations for SLS International (AMEX:SLS)

Receive News & Ratings for SLS International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SLS International and related companies with's FREE daily email newsletter.

Leave a Reply